July 23, 2025

Table 3 from Chemoimmunotherapy Outcomes and Prognostic Factors in Patients with Advanced, Low PD-L1–Expressing Non–Small Cell Lung Cancer

View Full Paper

Ask AI

Bookmark

MAIN FINDING: Chemoimmunotherapy significantly impacts progression-free survival (PFS) in low PD-L1 non-small cell lung cancer patients.
KEY EVIDENCE: Both univariate and multivariate analyses underline the role of ICI and chemotherapy in treatment outcomes.
APPROACH: The study uses patient data on ICI treatments combined with chemotherapy to assess PFS outcomes.
SIGNIFICANCE: Understanding prognostic factors enhances treatment strategies for advanced lung cancer patients with low PD-L1 expression.

Implication

Univariate and multivariate analysis shows impact of chemotherapy and ICI on PFS in advanced cancer cases, highlighting prognostic factors.

Univariate and multivariate analysis of PFS in patients treated with ICI and chemotherapy

No takes yet. Share an insight, caveat, or question.

Hata et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Univariate and multivariate analysis shows impact of chemotherapy and ICI on PFS in advanced cancer cases, highlighting prognostic factors.

Univariate and multivariate analysis of PFS in patients treated with ICI and chemotherapy